Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-dose dasiglucagon rescue therapy in children under 6 years with type 1 diabetes
2025-000121-13Phase 3
- Sponsor
- Zealand Pharma
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dasiglucagon in hypoglycaemia and diabetes mellitus type 1 (T1D), sponsored by Zealand Pharma. Primary endpoint: Change From Baseline in Plasma Glucose Concentration at 30 Minutes After IMP Injection.
02
Drugs
dasiglucagon
03
Conditions
hypoglycaemiadiabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-000121-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000121-13.